Search

Rachel A Altura

from Belle Mead, NJ
Age ~57
Get Report
Also known as:
Rachel A A Holloway, Rachel A Holloway, Ra Altura
Phone and address:
84 West St, Montgomery, NJ 08502
(781) 201-9905
Related to:
Rebecca F Holloway, 24
Connected to:
Alfredo F Altura, 65Azhaar Alturkistani, 42Mohamed A Alturki, 63Mohammad Alturkistani, 45Gosvener Altus, 57Richard C Altus, 66Joseph M Altusky, 65Lisset Altuve, 56Reinaldo Altuve, 59Salvador A Altuve, 39

Rachel Altura Phones & Addresses

  • 84 West St, Belle Mead, NJ 08502 (781) 201-9905
  • Westerly, RI
  • 20 Highland St, Sharon, MA 02067 (781) 806-5858
  • 2424 Sherwood Rd, Columbus, OH 43209
  • 1018 Sugar Hill Pl, Columbus, OH 43230
  • 184 Stanwood Rd, Columbus, OH 43209 (614) 239-7739
  • Bexley, OH
  • Des Moines, IA
  • Cordova, TN
  • Saint Louis, MO

Work

Company: Tomorrow Fund Clinic Address: 593 Eddy St Suite 105, Providence, RI 02903 Phones: (401) 444-5241

Education

School / High School: Washington Center / School of Medicine 1992

Languages

English • Spanish

Awards

Healthgrades Honor Roll

Ranks

Certificate: Pediatric Oncology & Pediatric Hematology, 2004

Specialities

Pediatric Hematology & Oncology

Professional Records

Medicine Doctors

Rachel Altura Photo 1

Dr. Rachel A Altura, Providence RI - MD (Doctor of Medicine)

View page
Specialties:
Pediatric Hematology & Oncology
Address:
Tomorrow Fund Clinic
593 Eddy St Suite 105, Providence, RI 02903
(401) 444-5241 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2004
Pediatrics, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Spanish
Hospitals:
Tomorrow Fund Clinic
593 Eddy St Suite 105, Providence, RI 02903

Rhode Island Hospital
593 Eddy Street, Providence, RI 02903
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1992
Medical School
Chldns Hosp-Wash U
Graduated: 1992
Medical School
St Jude Chldns Hosp
Graduated: 1992
Rachel Altura Photo 2

Rachel A. Altura

View page
Specialties:
Pediatric Hematology-Oncology
Work:
Tomorrow Fund Clinic
593 Eddy St STE 105, Providence, RI 02903
(401) 444-5241 (phone), (401) 444-7887 (fax)
Education:
Medical School
Washington University School of Medicine
Graduated: 1992
Procedures:
Bone Marrow Biopsy
Chemotherapy
Conditions:
Leukemia
Anemia
Hemolytic Anemia
Hodgkin's Lymphoma
Iron Deficiency Anemia
Languages:
English
Spanish
Description:
Dr. Altura graduated from the Washington University School of Medicine in 1992. She works in Providence, RI and specializes in Pediatric Hematology-Oncology. Dr. Altura is affiliated with Rhode Island Hospital and Women & Infants Hospital.
Rachel Altura Photo 3

Rachel Allison Altura, Providence RI

View page
Specialties:
Pediatric Hematologist / Oncologist
Address:
593 Eddy St, Providence, RI 02903
Education:
Washington University, School of Medicine - Doctor of Medicine
St. Jude Children's Research Hospital - Fellowship - Pediatric Hematology/Oncology (Pediatrics)
St. Louis Children's Hospital - Residency - Pediatrics
Board certifications:
American Board of Pediatrics Certification in Pediatrics
American Board of Pediatrics Sub-certificate in Pediatric Hematology/Oncology (Pediatrics)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Rachel A. Altura
Oncology, Medical Doctor
The Tomorrow Fund
Helping Children With Cncer In Ri, Supporting Ri Hospita's Pediatric Oncology Program Plus Supporting Hasbro Children's Tomorrow Fund Outpatient Clinic. · Social Services · Other Grantmaking & Giving Services
593 Eddy St, Providence, RI 02903
(401) 444-8811, (401) 444-4542
Rachel Allison Altura
Rachel Altura MD
Pediatric Oncologist · Pediatrician
593 Eddy St #105, Providence, RI 02903
(401) 444-5241

Publications

Us Patents

Survivin-Directed Rna Interference-Compositions And Methods

View page
US Patent:
20060276423, Dec 7, 2006
Filed:
Apr 18, 2006
Appl. No.:
11/406740
Inventors:
Rachel Altura - Bexley OH, US
Hugo Caldas - Columbus OH, US
Michael Holloway - Bexley OH, US
International Classification:
A61K 48/00
A61K 31/337
C12Q 1/68
C07H 21/02
US Classification:
514044000, 514449000, 435006000, 536023200
Abstract:
The present invention is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short interfering RNAs (si-RNAs) or through administration of DNA sequences yielding the expression of short hairpin RNAs (sh-RNAs).

Apoptosis-Inducing Genes For Treating Cancer

View page
US Patent:
20090239937, Sep 24, 2009
Filed:
Aug 26, 2005
Appl. No.:
11/661224
Inventors:
Hugo Caldas - Winston-Salem NC, US
Rachel A. Altura - Sharon MA, US
International Classification:
A61K 31/7088
C07H 21/04
C07H 1/00
A61P 35/00
US Classification:
514 44 R, 536 231, 536124
Abstract:
The invention provides materials and methods related to the use of recombinant nucleic acid molecules containing an expression control element of an inhibitor of apoptosis protein (IAP) gene operatively linked to a coding region for an active cytotoxic/cytolytic agent. The recombinant molecules are used in methods to treat a variety of diseases and disorders, including a wide range of cancers.

Use Of Biomarkers In Identifying Patients That Will Be Responsive To Treatment With A Prmt5 Inhibitor

View page
US Patent:
20230062119, Mar 2, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/783938
Inventors:
- Rahway NJ, US
Rachel Allison Altura - Westerly RI, US
Razvan Cristescu - Newton MA, US
David John Curtis - Camberwell, Victoria, AU
Ian Philip Street - Williamstown, Victoria, AU
Assignee:
Merck Sharp & Dohme LLC - Rahway NJ
International Classification:
C12Q 1/6886
Abstract:
The present invention includes methods of identifying a patient who will likely be responsive to treatment with a protein arginine N-methyltransferase 5 inhibitor, or a pharmaceutically acceptable salt thereof, and methods of treating the same.

Methods For Treating Cancer Using A Combination Of A Pd-1 Antagonist, An Ilt4 Antagonist, And Chemotherapeutic Agents

View page
US Patent:
20230050449, Feb 16, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/785590
Inventors:
- Rahway NJ, US
Rachel A. Altura - Westerly RI, US
Bilal Piperdi - Teaneck NJ, US
Assignee:
Merck Sharp & Dohme LLC - Rahway NJ
International Classification:
C07K 16/28
A61K 31/555
A61K 31/519
A61P 35/00
Abstract:
Provided herein are methods of treating cancer (e.g., NSCLC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) one or more chemotherapeutic agents. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer.

Methods For Treating Cancer With Anti Pd-1 Antibodies And Anti Ctla4 Antibodies

View page
US Patent:
20210047409, Feb 18, 2021
Filed:
Feb 8, 2019
Appl. No.:
16/966988
Inventors:
Mallika LALA - Rahway NJ, US
Lokesh JAIN - Rahway NJ, US
Mengyao LI - Springfield NJ, US
Rachel Allison ALTURA - Rahway NJ, US
Archie Ngai-chiu TSE - Long Island City NY, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07K 16/28
A61K 39/395
A61P 35/00
Abstract:
The present invention relates to methods for treating cancer in a patient comprising administering an anti-PD-1 antibody or antigen binding fragment thereof in specific amounts to the patient about every six weeks, in combination with administering an anti-CTLA4 antibody to the patient about every six weeks. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and a dosage of an anti-CTLA4 antibody or antigen-binding fragment thereof, and uses thereof for treating cancer.

Newcastle Disease Viruses And Uses Thereof

View page
US Patent:
20200061184, Feb 27, 2020
Filed:
May 11, 2018
Appl. No.:
16/611813
Inventors:
- New York NY, US
- Rahway NJ, US
Svetlana Sadekova - Mountain View CA, US
Rachel Allison Altura - Belle Mead NJ, US
Uyen Phan - San Jose CA, US
Brian B. Haines - Jamaica Plain MA, US
Jedd D. Wolchok - New York NY, US
Assignee:
Icahn School of Medicine at Mount Sinai - New York NY
Memorial Sloan Kettering Cancer Center - New York NY
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 39/17
A61K 35/768
A61P 35/00
A61K 39/00
A61K 39/395
C07K 14/54
C07K 16/28
C12N 15/86
Abstract:
Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.

Combination Therapy With Anti-Cd73 Antibodies

View page
US Patent:
20190284293, Sep 19, 2019
Filed:
Mar 3, 2017
Appl. No.:
16/081115
Inventors:
- Princeton NJ, US
Alan J. KORMAN - Piedmont CA, US
Bryan C. BARNHART - San Francisco CA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Mohan SRINIVASAN - Cupertino CA, US
Karla A. HENNING - Milpitas CA, US
Ming LEI - Princeton NJ, US
Emanuela SEGA - Cupertino CA, US
Angela GOODENOUGH - Morrisville PA, US
Guodong CHEN - East Brunswick NJ, US
John S. SACK - Lawrenceville NJ, US
Richard Y. HUANG - Bridgewater NJ, US
Martin J. CORBETT - Mount Holly NJ, US
Liang SCHWEIZER - Shanghai PR, CN
Sandra V. HATCHER - Hillsborough NJ, US
Rachel A. ALTURA - Belle Mead NJ, US
Haichun HUANG - Fremont CA, US
Pingping ZHANG - Cupertino CA, US
Edward J. HILT - Yardley PA, US
Michael Nathan HEDRICK - Doylestown PA, US
International Classification:
C07K 16/28
A61K 9/00
Abstract:
Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.
Control profile
Rachel A Altura from Belle Mead, NJ, age ~57 Get Report